Evoke Pharma receives US patent covering nasal formulation of metoclopramide Gimoti

Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued US Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the company’s commercially available and FDA-approved nasal formulation of metoclopramide, Gimoti. 

This new patent, issued on November 14, 2023, provides Evoke with additional intellectual property protections with claims to metoclopramide being delivered intranasally, amongst others. Evoke continues to see significant commercial value, particularly with the rising popularity of GLP-1 agonist medications for diabetes which are potentially unmasking gastroparesis (stomach paralysis) in larger groups of patients. Gimoti is the only outpatient, non-oral drug labelled for the treatment of acute and recurrent diabetic gastroparesis. The ability to take the medication non-orally is important as gastroparesis causes tablets to be unpredictably absorbed. Pills may linger in the stomach instead of being passed into the intestines for absorption or not absorbed at all due to one of the key symptoms of the disease, vomiting.

“We continue to witness the significance of Gimoti in the marketplace through various validation points, including patient and market data, growing revenues, and a robust stream of patent protections. We are thrilled to continue providing patients a life-changing experience with diabetic gastroparesis treatment and bolster the already promising commercial opportunity for Gimoti,” commented Matt D’Onofrio, president and COO of Evoke Pharma.

Gimoti is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!